Literature DB >> 34697144

The Inflammatory Process Modulates the Expression and Localization of WT1 in Podocytes Leading to Kidney Damage.

Mariela Arellano-Rodríguez1, Pablo Zapata-Benavides2, Norma Cesilia Arellano-Rodríguez1, Juan Manuel Izaguirre-Álvarez1, Moisés Armides Franco-Molina1, Felipe DE Jesús Torres Del Muro1, Edgar Mendoza-Gamboa1, Adolfo Soto-Domínguez3, Santiago Saavedra-Alonso1, Cristina Rodríguez-Padilla1.   

Abstract

BACKGROUND/AIM: Wilms' tumor 1 (WT1) is involved in the development of the urogenital system and is expressed in podocytes throughout life. Inflammation of renal glomeruli causes renal damage-induced nephrotic syndrome and steroid-resistant nephrotic syndrome have mutations in the WT1 gene. The aim of this work was to determine if the inflammatory process modulates the expression and localization of WT1 in podocytes that cause kidney damage using lipopolysaccharide (LPS)-treated mice as a sepsis model.
MATERIALS AND METHODS: In investigation of renal damage, proteinuria and histology were analyzed. WT1 modulation was analyzed by indirect immunofluorescence, immunohistochemistry and western blot assays, and proinflammatory cytokines were analyzed by quantitative polymerase chain reaction assay.
RESULTS: WT1 expression decreased most at 24 and 36 h after the induction of inflammation and phosphorylated WT1 was mainly localized in the cytoplasm, reduced nephrin mRNA expression and increased mRNA expression of tumor necrosis factor α and interleukin 1β.
CONCLUSION: These results indicate that the immune system plays an important role in the modulation of WT1, leading to kidney damage.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  WT1 phosphorylated; kidney; lipopolysaccharide; nephrotic syndrome; sepsis

Mesh:

Substances:

Year:  2021        PMID: 34697144      PMCID: PMC8627738          DOI: 10.21873/invivo.12608

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  38 in total

1.  Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation.

Authors:  Y Ye; B Raychaudhuri; A Gurney; C E Campbell; B R Williams
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

2.  WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.

Authors:  R E Palmer; A Kotsianti; B Cadman; T Boyd; W Gerald; D A Haber
Journal:  Curr Biol       Date:  2001-11-13       Impact factor: 10.834

3.  Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations.

Authors:  Gil Chernin; Virginia Vega-Warner; Dominik S Schoeb; Saskia F Heeringa; Bugsu Ovunc; Pawaree Saisawat; Roxana Cleper; Fatih Ozaltin; Friedhelm Hildebrandt
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

4.  Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain.

Authors:  Y Sakamoto; M Yoshida; K Semba; T Hunter
Journal:  Oncogene       Date:  1997-10-23       Impact factor: 9.867

5.  Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product.

Authors:  W Bruening; P Moffett; S Chia; G Heinrich; J Pelletier
Journal:  FEBS Lett       Date:  1996-09-09       Impact factor: 4.124

6.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

Authors:  Phoenix A Ho; Rong Zeng; Todd A Alonzo; Robert B Gerbing; Kristen L Miller; Jessica A Pollard; Derek L Stirewalt; Nyla A Heerema; Susana C Raimondi; Betsy Hirsch; Janet L Franklin; Beverly Lange; Soheil Meshinchi
Journal:  Blood       Date:  2010-04-22       Impact factor: 22.113

7.  Endogenous Inhibitors of Kidney Inflammation.

Authors:  Jessica Trostel; Gabriela E Garcia
Journal:  J Nephrol Res       Date:  2015-10

8.  Inherited WT1 mutation in Denys-Drash syndrome.

Authors:  M J Coppes; G J Liefers; M Higuchi; A B Zinn; J W Balfe; B R Williams
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

9.  Cytoplasmic Localization of WT1 and Decrease of miRNA-16-1 in Nephrotic Syndrome.

Authors:  Pablo Zapata-Benavides; Mariela Arellano-Rodríguez; Juan José Bollain-Y-Goytia; Moisés Armides Franco-Molina; Gloria Azucena Rangel-Ochoa; Esperanza Avalos-Díaz; Rafael Herrera-Esparza; Cristina Rodríguez-Padilla
Journal:  Biomed Res Int       Date:  2017-02-19       Impact factor: 3.411

10.  Mycophenolate Mofetil Ameliorates Diabetic Nephropathy in db/db Mice.

Authors:  Jung-Woo Seo; Yang Gyun Kim; Sang Ho Lee; Arah Lee; Dong-Jin Kim; Kyung-Hwan Jeong; Kyung Hye Lee; Seung Joon Hwang; Jong Shin Woo; Sung Jig Lim; Weon Kim; Ju-Young Moon
Journal:  Biomed Res Int       Date:  2015-08-04       Impact factor: 3.411

View more
  1 in total

1.  Evaluating Established Roles, Future Perspectives and Methodological Heterogeneity for Wilms' Tumor 1 (WT1) Antigen Detection in Adult Renal Cell Carcinoma, Using a Novel N-Terminus Targeted Antibody (Clone WT49).

Authors:  Dorin Novacescu; Talida Georgiana Cut; Alin Adrian Cumpanas; Silviu Constantin Latcu; Razvan Bardan; Ovidiu Ferician; Cosmin-Ciprian Secasan; Andrei Rusmir; Marius Raica
Journal:  Biomedicines       Date:  2022-04-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.